Trial Profile
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 15 Jul 2019 New trial record